荆花胃康胶丸联合铋剂四联疗法治疗Hp感染十二指肠球部溃疡的内镜疗效和Hp根除率评价  

Endoscopic Efficacy and Hp Eradication Rate of Duodenal Bulbar Ulcer Infected by Hp Treated with Jinghua Weikang Capsule Combined with Bismuth Agent

作　　者：王凤磊[1] 李静[1] 张福文[1] 李志红[2] WANG Fenglei;LI Jing;ZHANG Fuwen;LI Zhihong(Department of Spleen and Gastroenterology Division 2,Dongzhimen Hospital Bejing University of Chinese Medicine,Beijing 101121,China;Department of Spleen and Gastroenterology Division 1,Dongzhimen Hospital Beijing University of Chinese Medicine,Beijing 100700,China)

机构地区：[1]北京中医药大学东直门医院,脾胃病科二区,北京101121 [2]北京中医药大学东直门医院,脾胃病科一区,北京100700

出　　处：《药物生物技术》2024年第6期678-682,共5页Pharmaceutical Biotechnology

基　　金：通州区高层次人才发展支持计划(No.YHLD2019006)。

摘　　要：探究荆花胃康胶丸联合铋剂四联疗法对幽门螺杆菌(Hp)感染十二指肠球部溃疡(DU)患者内镜疗效和Hp根除率的影响,旨在为临床治疗提供循证医学证据。运用数字表法将2020年1月至2023年5月在本院就诊的82例Hp感染DU患者随机分为对照组(n=41)和联合组(n=41),分别采取铋剂四联疗法治疗、荆花胃康胶丸联合铋剂四联疗法治疗,对比2组内镜疗效、Hp根除率、临床症状改善情况以及胃蛋白酶原[胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)]、胃泌素17(G-17)水平,并统计用药安全性。联合组治疗后临床总有效率和Hp根除率均为95.12%,高于对照组80.49%(P<0.05),腹痛、腹胀、嗳气和反酸症状评分低于对照组(P<0.05),PGⅠ、PGⅡ和G-17水平低于对照组(P<0.05)。相较单独铋剂四联疗法治疗,荆花胃康胶丸联合铋剂四联疗法治疗Hp感染DU疗效更佳,其在保证内镜疗效的同时,可明显提高Hp根除率,缓解临床症状,调节胃蛋白酶原和G-17水平,不良反应少。To explore the effect of Jinghua Weikang capsule combined with bismuth quadruple therapy on endoscopic efficacy and Helicobacter pylori(Hp)eradication rate in patients with Hp infected duodenal bulb ulcer(DU),aiming to provide evidence-based medical evidence for clinical treatment,82 cases of DU patients with Hp infection treated in the hospital from January 2020 to May 2023 were randomly divided into control group(n=41)and combined group(n=41)by digital table method,and were treated with bismuth quadruple therapy or Jinghua Weikang capsule combined with bismuth quadruple therapy,respectively.The endoscopic efficacy,eradication rate of Hp,improvement of clinical symptoms,and levels of pepsinogen[pepsinogen Ⅰ(PG Ⅰ),pepsinogen Ⅰ(PG Ⅱ)],gastrin 17(G-17),and the drug safety was analyzed.After treatment,the total effective rate and Hp eradication rate of combined group were 95.12%,higher than that of control group 80.49%(P<0.05),the symptom scores of abdominal pain,abdominal distension,belching and acid reflux were lower than those of control group(P<0.05),and the levels of PG I,PG I and G-17 were lower than those of control group(P<0.05).Compared with bismuth quadruple therapy alone,Jinghua Weikang capsule combined with bismuth quadruple therapy has better efficacy in the treatment of Hp infection DU,while ensuring the healing effect of the mucosa under endoscopy,which can significantly improve the eradication rate of Hp,relieve clinical symptoms,regulate the level of pepsinogen and G-17,and reduce inflammation.There are few adverse reactions,which is worthy of clinical promotion.

关 键 词：十二指肠球部溃疡 荆花胃康胶丸 铋剂四联疗法 幽门螺杆菌 胃蛋白酶原 胃泌素17 疗效 根除率 

分 类 号：R541[医药卫生—心血管疾病]